{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:54:30Z","timestamp":1773928470755,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39135-w","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:22:55Z","timestamp":1771219375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nardosinone improves levodopa-induced dyskinesia in Parkinsonian rats through the microbiota\u2013gut\u2013brain axis"],"prefix":"10.1038","volume":"16","author":[{"given":"Jingwen","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuangzhuang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"39135_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/jpd-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R. et al. The emerging evidence of the Parkinson pandemic. J. Parkinsons Disease. 8, S3\u2013S8. https:\/\/doi.org\/10.3233\/jpd-181474 (2018).","journal-title":"J. Parkinsons Disease"},{"key":"39135_CR2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","volume":"101","author":"MM McGregor","year":"2019","unstructured":"McGregor, M. M. & Nelson, A. B. Circuit mechanisms of parkinson\u2019s disease. Neuron 101, 1042\u20131056. https:\/\/doi.org\/10.1016\/j.neuron.2019.03.004 (2019).","journal-title":"Neuron"},{"key":"39135_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad064","author":"KML Cramb","year":"2023","unstructured":"Cramb, K. M. L. et al. Impaired dopamine release in parkinson\u2019s disease. Brain https:\/\/doi.org\/10.1093\/brain\/awad064 (2023).","journal-title":"Brain"},{"key":"39135_CR4","doi-asserted-by":"publisher","unstructured":"Kwon, D. K. et al. Levodopa-Induced dyskinesia in Parkinson\u2019s Disease: Pathogenesis and emerging treatment strategies. Cells 11. https:\/\/doi.org\/10.3390\/cells11233736 (2022).","DOI":"10.3390\/cells11233736"},{"key":"39135_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/npp.2011.212","volume":"37","author":"Y Smith","year":"2012","unstructured":"Smith, Y. et al. Parkinson\u2019s disease therapeutics: new developments and challenges since the introduction of Levodopa. Neuropsychopharmacology 37, 213\u2013246. https:\/\/doi.org\/10.1038\/npp.2011.212 (2012).","journal-title":"Neuropsychopharmacology"},{"key":"39135_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/s1474-4422(17)30004-2","volume":"16","author":"V Voon","year":"2017","unstructured":"Voon, V. et al. Impulse control disorders and levodopa-induced dyskinesias in parkinson\u2019s disease: an update. Lancet Neurol. 16, 238\u2013250. https:\/\/doi.org\/10.1016\/s1474-4422(17)30004-2 (2017).","journal-title":"Lancet Neurol."},{"key":"39135_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2013.10.018","volume":"556","author":"YH Zhang","year":"2013","unstructured":"Zhang, Y. H. et al. The relationship between the phenotype of parkinson\u2019s disease and levodopa-induced dyskinesia. Neurosci. Lett. 556, 109\u2013112. https:\/\/doi.org\/10.1016\/j.neulet.2013.10.018 (2013).","journal-title":"Neurosci. Lett."},{"key":"39135_CR8","doi-asserted-by":"publisher","unstructured":"Munoz, A. et al. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson\u2019s Disease and Adverse Effects of L-DOPA. Front Neuroanat. 14 https:\/\/doi.org\/10.3389\/fnana.2020.00026 (2020).","DOI":"10.3389\/fnana.2020.00026"},{"key":"39135_CR9","doi-asserted-by":"publisher","unstructured":"Yang, K. et al. Circuit mechanisms of L-DOPA-Induced dyskinesia (LID). Front. NeuroSci. 15 https:\/\/doi.org\/10.3389\/fnins.2021.614412 (2021).","DOI":"10.3389\/fnins.2021.614412"},{"key":"39135_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26103","volume":"30","author":"EV Mosharov","year":"2015","unstructured":"Mosharov, E. V., Borgkvist, A. & Sulzer, D. Presynaptic effects of Levodopa and their possible role in dyskinesia. Mov. Disord. 30, 45\u201353. https:\/\/doi.org\/10.1002\/mds.26103 (2015).","journal-title":"Mov. Disord."},{"key":"39135_CR11","doi-asserted-by":"publisher","unstructured":"Baizabal-Carvallo, J. F., Alonso-Juarez, M. & Fekete, R. Intestinal Decontamination Therapy for Dyskinesia and Motor Fluctuations in Parkinson\u2019s Disease. Front. Neurol. 12 https:\/\/doi.org\/10.3389\/fneur.2021.729961 (2021).","DOI":"10.3389\/fneur.2021.729961"},{"key":"39135_CR12","doi-asserted-by":"crossref","unstructured":"Long-Smith, C. et al. Microbiota-gut-brain axis: New therapeutic opportunities.  Annu. Rev. Pharmacol. Toxicol.   60, 477\u2013502  (2020).","DOI":"10.1146\/annurev-pharmtox-010919-023628"},{"key":"39135_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.parkreldis.2021.12.012","volume":"95","author":"K Takahashi","year":"2022","unstructured":"Takahashi, K. et al. Altered gut microbiota in parkinson\u2019s disease patients with motor complications. Parkinsonism Relat. Disord. 95, 11\u201317. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.12.012 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"39135_CR14","doi-asserted-by":"crossref","unstructured":"Ghoneum, M. H.et al. Protective effect of Biobran\/MGN-3 against sporadic Alzheimer\u2019s disease mouse model: Possible role of oxidative stress and apoptotic pathways. Oxid. Med. Cell. Longev. 2021, 8845064 (2021).","DOI":"10.1155\/2021\/8845064"},{"key":"39135_CR15","doi-asserted-by":"publisher","first-page":"666502","DOI":"10.3389\/fphar.2021.666502","volume":"12","author":"H EL SAYED N S KEA, GHONEUM M","year":"2021","unstructured":"EL SAYED N S KEA, GHONEUM M, H. Enhancement of Insulin\/PI3K\/Akt signaling pathway and modulation of gut Microbiome by probiotics fermentation Technology, a Kefir grain Product, in sporadic alzheimer\u2019s disease model in mice. Front. Pharmacol. 12, 666502 (2021).","journal-title":"Front. Pharmacol."},{"key":"39135_CR16","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.wneu.2019.03.056","volume":"126","author":"ML Martini","year":"2019","unstructured":"Martini, M. L., Mocco, J. & Panov, F. Neurosurgical approaches to Levodopa-Induced dyskinesia. World Neurosurg. 126, 376\u2013382. https:\/\/doi.org\/10.1016\/j.wneu.2019.03.056 (2019).","journal-title":"World Neurosurg."},{"key":"39135_CR17","unstructured":"Commission, N. P. Pharmacopoeia of the People\u2019s Republic of China (A Medical Science and Technology, 2020)."},{"key":"39135_CR18","doi-asserted-by":"publisher","unstructured":"Das, G. et al. Plant species of Sub-Family Valerianaceae-A review on its effect on the central nervous system. Plants-Basel 10. https:\/\/doi.org\/10.3390\/plants10050846 (2021).","DOI":"10.3390\/plants10050846"},{"key":"39135_CR19","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11011-018-0261-z","volume":"33","author":"S Razack","year":"2018","unstructured":"Razack, S. et al. Anxiolytic actions of nardostachys Jatamansi via GABA benzodiazepine channel complex mechanism and its biodistribution studies. Metab. Brain Dis. 33, 1533\u20131549. https:\/\/doi.org\/10.1007\/s11011-018-0261-z (2018).","journal-title":"Metab. Brain Dis."},{"key":"39135_CR20","doi-asserted-by":"publisher","unstructured":"Wang, M. et al. A review on traditional uses, phytochemistry, pharmacology, toxicology and the analytical methods of the genus nardostachys. J. Ethnopharmacol. 280 https:\/\/doi.org\/10.1016\/j.jep.2021.114446 (2021).","DOI":"10.1016\/j.jep.2021.114446"},{"key":"39135_CR21","first-page":"5946","volume":"38","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. Research progress on the treatment of Levodopa induced dyskinesia with traditional Chinese medicine. China J. Traditional Chin. Med. Pharm. 38, 5946\u20135950 (2023).","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"39135_CR22","first-page":"134","volume":"53","author":"L Jia-yuan","year":"2022","unstructured":"Jia-yuan, L. et al. Mechanism of nardostachys Jatamansi on levodopa-induced dyskinesia in rats based on Nrf2\/D1R-ERK signaling pathway. Chin. Traditional Herb. Drugs. 53, 134\u2013142 (2022).","journal-title":"Chin. Traditional Herb. Drugs"},{"key":"39135_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.19540\/j.cnki.cjcmm.20210922.701","volume":"47","author":"W Guo-hui","year":"2022","unstructured":"Guo-hui, W. et al. Effects of nardostachys Jatamansi on gut microbiota of rats with parkinson\u2019s disease. China J. Traditional Chin. Med. Pharm. 47, 499\u2013510. https:\/\/doi.org\/10.19540\/j.cnki.cjcmm.20210922.701 (2022).","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"39135_CR24","doi-asserted-by":"publisher","unstructured":"Bian, L. H. et al. Nardosinone alleviates Parkinson\u2019s disease symptoms in mice by regulating dopamine D2 Receptor. Evid.-Based Complement. Altern. Med.  (2021). https:\/\/doi.org\/10.1155\/2021\/6686965","DOI":"10.1155\/2021\/6686965"},{"key":"39135_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.nbd.2009.01.016","volume":"34","author":"JR Cannon","year":"2009","unstructured":"Cannon, J. R. et al. A highly reproducible rotenone model of parkinson\u2019s disease. Neurobiol. Dis. 34, 279\u2013290. https:\/\/doi.org\/10.1016\/j.nbd.2009.01.016 (2009).","journal-title":"Neurobiol. Dis."},{"key":"39135_CR26","doi-asserted-by":"crossref","unstructured":"Farid, H. et al. PI3K\/AKT signaling activation by roflumilast ameliorates rotenone-induced Parkinson\u2019s disease in rats.  Inflammopharmacology 32, 1421\u20131437  (2023).","DOI":"10.1007\/s10787-023-01305-x"},{"issue":"1","key":"39135_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-160197","volume":"54","author":"ISSK Olsen","year":"2016","unstructured":"Olsen, I. S. S. K. Inflammasome involvement in alzheimer\u2019 s disease. J. Alzheimers Dis. 54 (1), 45\u201353 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"39135_CR28","doi-asserted-by":"crossref","unstructured":"Badawi, G. A. et al. Sitagliptin and liraglutide modulate L-dopa effect and attenuate dyskinetic movements in Rotenone-Lesioned rats. Neurotox. Res. 35(3), 635\u2013653 (2019).","DOI":"10.1007\/s12640-019-9998-3"},{"key":"39135_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.molbrainres.2004.11.007","volume":"134","author":"CM Testa","year":"2005","unstructured":"Testa, C. M., Sherer, T. B. & Greenamyre, J. T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia Nigra cultures. Mol. Brain Res. 134, 109\u2013118. https:\/\/doi.org\/10.1016\/j.molbrainres.2004.11.007 (2005).","journal-title":"Mol. Brain Res."},{"key":"39135_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi, K. et al. The lewy body in parkinson\u2019s disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495\u2013508. https:\/\/doi.org\/10.1007\/s12035-012-8280-y (2013).","journal-title":"Mol. Neurobiol."},{"key":"39135_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00441-004-0956-9","volume":"318","author":"H Braak","year":"2004","unstructured":"Braak, H. et al. Stages in the development of parkinson\u2019s disease-related pathology. Cell Tissue Res. 318, 121\u2013134. https:\/\/doi.org\/10.1007\/s00441-004-0956-9 (2004).","journal-title":"Cell Tissue Res."},{"key":"39135_CR32","doi-asserted-by":"publisher","unstructured":"Shimozawa, A. et al. Effect of L-DOPA\/Benserazide on propagation of pathological \u03b1-Synuclein. Front. NeuroSci. 13 https:\/\/doi.org\/10.3389\/fnins.2019.00595 (2019).","DOI":"10.3389\/fnins.2019.00595"},{"key":"39135_CR33","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s10072-020-04333-5","volume":"41","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Research advances on L-DOPA-induced dyskinesia: from animal models to human disease. Neurol. Sci. 41, 2055\u20132065. https:\/\/doi.org\/10.1007\/s10072-020-04333-5 (2020).","journal-title":"Neurol. Sci."},{"key":"39135_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.parkreldis.2013.08.017","volume":"20","author":"R Pahwa","year":"2014","unstructured":"Pahwa, R. et al. Randomized trial of IPX066, carbidopa\/levodopa extended release, in early parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 142\u2013148. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.08.017 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"39135_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1586\/14737175.2013.839235","volume":"13","author":"F Grandas","year":"2013","unstructured":"Grandas, F. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced parkinson\u2019s disease. Expert Rev. Neurother. 13, 1343\u20131353. https:\/\/doi.org\/10.1586\/14737175.2013.839235 (2013).","journal-title":"Expert Rev. Neurother."},{"key":"39135_CR36","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.2174\/1570159x21666221019115716","volume":"21","author":"KF Xu","year":"2023","unstructured":"Xu, K. F., Sheng, S. & Zhang, F. Relationship between gut bacteria and Levodopa metabolism. Curr. Neuropharmacol. 21, 1536\u20131547. https:\/\/doi.org\/10.2174\/1570159x21666221019115716 (2023).","journal-title":"Curr. Neuropharmacol."},{"key":"39135_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nrgastro.2009.35","volume":"6","author":"SH Rhee","year":"2009","unstructured":"Rhee, S. H., Pothoulakis, C. & Mayer, E. A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Reviews Gastroenterol. Hepatol. 6, 306\u2013314. https:\/\/doi.org\/10.1038\/nrgastro.2009.35 (2009).","journal-title":"Nat. Reviews Gastroenterol. Hepatol."},{"key":"39135_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481\u2013487. https:\/\/doi.org\/10.1038\/nature21029 (2017).","journal-title":"Nature"},{"key":"39135_CR39","doi-asserted-by":"publisher","unstructured":"Montoya, A. et al. Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation. J. Neuroinflamm. 16 https:\/\/doi.org\/10.1186\/s12974-019-1652-8 (2019).","DOI":"10.1186\/s12974-019-1652-8"},{"key":"39135_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2019.05.019","volume":"81","author":"K Lanza","year":"2019","unstructured":"Lanza, K. et al. Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat. Neurobiol. Aging. 81, 190\u2013199. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2019.05.019 (2019).","journal-title":"Neurobiol. Aging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39135-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39135-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39135-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:36:06Z","timestamp":1773916566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39135-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39135"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39135-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9364"}}